PREVALENCE AND PRINCIPLES OF TREATMENT OF BARRETT'S ESOPHAGUS


Cite item

Full Text

Abstract

The article analyzes information on the prevalence and principles of treatment of Barretts esophagus. In Russia, the prevalence of Barretts esophagus is range from 1,5 to 2,9 %. In the US it varies from 1,5 to 5,0 %. Currently, the leading methods of treatment of Barretts esophagus are long-term administration of proton pump inhibitors or surgical interventions, including radiofrequency ablation.

References

  1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103(3):788-97.
  2. Falk GW. Barrett's esophagus. Gastroenterology 2002;122(6):1569-91.
  3. Sharma P, Falk GW, Sampliner R, et al. Management of nondysplastic Barrett's esophagus: where are we now? Am J Gastroenterol 2009;104(4):805-08.
  4. Gatenby PA, Ramus JR, Caygill CP, et al. Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus 2009;22(2):133-42.
  5. Anandasabapathy S, Jhamb J, Davila M, et al. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 2007;109(4):668-74.
  6. Буторин Н.Н., Ржавичева О.С., Хоменко О.В., Цуканов В.В. и др. Распространенность и клинические аспекты пищевода Барретта в Республике Хакасия // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии 2010. № 5. С. 16-21.
  7. Vakil N, van Zanten S, Kahrilas P, et al. The Monreal Definition and Classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900-20.
  8. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's esophagus and columnar metaplasia. Aliment Pharmacol Ther 2004;20(5):40-47.
  9. Ушаева Л.А., Балалыкин Д.А. Хромоэндоскопия в диагностике злокачественных новообразований // Эндоскопическая хирургия 2008. № 5. С. 32-33.
  10. Tytgat GNJ, Guili R, DeMeester TR, et al. What are the endoscopic criteria for diagnosing columnar metaplasia? The Esophageral Mucosa Amsterdam: Elsevier, 1994:795-98.
  11. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127(1):310-30.
  12. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125(6):1670-77.
  13. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: An endoscopic study. Gastroenterology 2005;129(6):1825-31.
  14. Hongo M. Review article: Barrett's esophagus and carcinoma in Japan. Aliment Pharmacol Ther 2004;20(8):50-54.
  15. Wang A, Mattek NC, Holub JL, et al. Prevalence of complicated gastroesophageal reflux disease and Barrett's esophagus among racial groups in a multicenter consortium. Dig Dis Sci 2009;54(5):964-71.
  16. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99(10):1877-83.
  17. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180(8):387-91.
  18. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124(1):47-56.
  19. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett' s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99(7):545-57.
  20. Wassenaar EB, Oelschlager BK. Effect of medical and surgical treatment of Barrett's metaplasia. World J Gastroenterol 2010;16(30):3773-79.
  21. Hofstetter WL, Peters JH, DeMeester T, et al. Long-term outcome of antireflux surgery in patients with Barrett' s esophagus. Ann Surg 2001;234(4):532-39.
  22. Csendes A, Burdiles P, Braghetto I, et al. Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 2004;8(4):434-41.
  23. Rees JR, Lao-Sirieix P, Wong A, et al. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010;1:CD004060.
  24. Jones R, Patrikios T. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int J Clin Pract 2008;62(12):1844-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies